ABSTRACT
The degradation of metoprolol (MTP) by the UV/sulfite with oxygen as an advanced reduction process (ARP) and that without oxygen as an advanced oxidation process (AOP) was comparatively studied herein. The degradation of MTP by both processes followed the first-order rate law with comparable reaction rate constants of 1.50×10-3sec-1 and 1.20×10-3sec-1, respectively. Scavenging experiments demonstrated that both eaq- and H⢠played a crucial role in MTP degradation by the UV/sulfite as an ARP, while SO4â¢- was the dominant oxidant in the UV/sulfite AOP. The degradation kinetics of MTP by the UV/sulfite as an ARP and AOP shared a similar pH dependence with a minimum rate obtained around pH 8. The results could be well explained by the pH impacts on the MTP speciation and sulfite species. Totally six transformation products (TPs) were identified from MTP degradation by the UV/sulfite ARP, and two additional ones were detected in the UV/sulfite AOP. The benzene ring and ether groups of MTP were proposed as the major reactive sites for both processes based on molecular orbital calculations by density functional theory (DFT). The similar degradation products of MTP by the UV/sulfite process as an ARP and AOP indicated that eaq-/H⢠and SO4â¢- might share similar reaction mechanisms, primarily including hydroxylation, dealkylation, and H abstraction. The toxicity of MTP solution treated by the UV/sulfite AOP was calculated to be higher than that in the ARP by the Ecological Structure Activity Relationships (ECOSAR) software, due to the accumulation of TPs with higher toxicity.
Subject(s)
Water Pollutants, Chemical , Water Purification , Metoprolol/chemistry , Oxygen , Ultraviolet Rays , Water Pollutants, Chemical/chemistry , Oxidation-Reduction , Sulfites/chemistry , Kinetics , Water Purification/methodsABSTRACT
Combining solid phase microextraction (SPME) and mass spectrometry (MS) analysis has become increasingly important to many bioanalytical, environmental, and forensic applications due to its simplicity, rapid analysis, and capability of reducing matrix effects for complex samples. To further promote the adoption of SPME-MS based analysis and expand its application scope calls for efficient and convenient interfaces that couple the SPME sample handling with the efficient analyte ionization for MS. Here, we report a novel interface that integrates both the desorption and the ionization steps in one device based on the capillary vibrating sharp-edge spray ionization (cVSSI) method. We demonstrated that the cVSSI is capable of nebulizing liquid samples in a pulled-tip glass capillary with a battery powered function generator. The cVSSI device allows the insertion of a SPME probe into the spray capillary for desorption and then direct nebulization of the desorption solvent in situ. With the integrated interface, we have demonstrated rapid MS analysis of drug compounds from serum samples. Quantitative determination of various drug compounds including metoprolol, pindolol, acebutolol, oxprenolol, capecitabine, and irinotecan was achieved with good linearity (R2 = 0.97-0.99) and limit of detection ranging from 0.25 to 0.59 ng/mL without using a high voltage source. Only 3.5 µL of desorption solvent and 3 min desorption time were needed for the present method. Overall, we demonstrated a portable SPME-MS interface featuring high sensitivity, short analysis time, small footprint, and low cost, which makes it an attractive method for many applications requiring sample cleanup including drug compound monitoring, environmental sample analysis, and forensic sample analysis.
Subject(s)
Solid Phase Microextraction/instrumentation , Spectrometry, Mass, Electrospray Ionization/instrumentation , Carbamazepine/chemistry , Equipment Design , Limit of Detection , Metoprolol/chemistry , Pindolol/chemistry , Sensitivity and Specificity , Serum Albumin, Bovine/chemistryABSTRACT
Pharmaceuticals are found in waterbodies worldwide. Conventional sewage treatment plants are often not able to eliminate these micropollutants. Hence, Advanced Oxidation Processes (AOPs) have been heavily investigated. Here, metoprolol is exposed to UV irradiation, hydrogen peroxide, and ozonation. Degradation was analyzed using chemical kinetics both for initial and secondary products. Photo-induced irradiation enhanced by hydrogen peroxide addition accelerated degradation more than ozonation, leading to complete elimination. Degradation and transformation products were identified by high-performance liquid-chromatography coupled to high-resolution higher-order mass spectrometry. The proposed structures allowed to apply Quantitative Structure-Activity Relationship (QSAR) analysis to predict ecotoxicity. Degradation products were generally associated with a lower ecotoxicological hazard to the aquatic environment according to OECD QSAR toolbox and VEGA. Comparison of potential structural isomers suggested forecasts may become more reliable with larger databases in the future.
Subject(s)
Ecotoxicology , Metoprolol/analysis , Ozone/chemistry , Quantitative Structure-Activity Relationship , Sewage/chemistry , Wastewater/chemistry , Water Pollutants, Chemical/analysis , Algorithms , Bioreactors , Chromatography, High Pressure Liquid , Ecotoxicology/methods , Environmental Monitoring/methods , Hydrogen Peroxide/chemistry , Hydrogen-Ion Concentration , Kinetics , Metoprolol/chemistry , Oxygen/chemistry , Photochemistry , Photolysis , Software , Ultraviolet Rays , Water Pollutants, Chemical/chemistryABSTRACT
Nowadays anticancer drugs (ADs), like other pharmaceuticals, are recognized as new emerging pollutants, meaning that they are not commonly monitored in the environment; however, they have great potential to enter the environment and cause adverse effects there. The current scientific literature highlights the problem of their presence in the aquatic environment by publishing more and more results on their analytics and ecotoxicological evaluation. In order to properly assess the risk associated with the presence of ADs in the environment, it is also necessary to investigate the processes that are important in understanding the environmental fate of these compounds. However, the state of knowledge on mobility of ADs in the environment is still very limited. Therefore, the main aim of our study was to investigate the sorption potential of two anticancer drugs, 5-fluorouracil (5-FU) and methotrexate (MTX), onto different soils. Special attention was paid to the determination of the influence of pH and ionic strength as well as presence of co-contaminants (cadmium (Cd2+) and another pharmaceutical-metoprolol (MET)) on the sorption of 5-FU and MTX onto soil. The obtained distribution coefficient values (Kd) ranged from 2.52 to 6.36 L·kg-1 and from 6.79 to 12.94 L·kg-1 for 5-FU and MTX, respectively. Investigated compounds may be classified as slightly or low mobile in the soil matrix (depending on soil). 5-FU may be recognized as more mobile in comparison to MET. It was proved that presence of other soil contaminants may strongly influence their mobility in soil structures. The investigated co-contaminant (MET) caused around 25-fold increased sorption of 5-FU, whereas diminished sorption of MTX. Moreover, the influence of environmental conditions such as pH and ionic strength on their sorption has been clearly demonstrated.
Subject(s)
Environmental Monitoring/methods , Environmental Pollutants/chemistry , Fluorouracil/chemistry , Methotrexate/chemistry , Plant Extracts/chemistry , Soil Pollutants/chemistry , Soil/chemistry , Adsorption , Cadmium/chemistry , Environmental Monitoring/instrumentation , Environmental Pollutants/analysis , Hydrogen-Ion Concentration , Metoprolol/chemistry , Osmolar ConcentrationABSTRACT
Most of the active pharmaceutical ingredients like Metoprolol are oxidatively metabolized by liver enzymes, such as Cytochrome P450 monooxygenases into oxygenates and therefore hydrophilic products. It is of utmost importance to identify the metabolites and to gain knowledge on their toxic impacts. By using electrochemistry, it is possible to mimic enzymatic transformations and to identify metabolic hot spots. By introducing charged-tags into the intermediate, it is possible to detect and isolate metabolic products. The identification and synthesis of initially oxidized metabolites are important to understand possible toxic activities. The gained knowledge about the metabolism will simplify interpretation and predictions of metabolitic pathways. The oxidized products were analyzed with high performance liquid chromatography-mass spectrometry using electrospray ionization (HPLC-ESI-MS) and nuclear magnetic resonance (NMR) spectroscopy. For proof-of-principle, we present a synthesis of one pyridinated main oxidation product of Metoprolol.
Subject(s)
Metoprolol/chemistry , Metoprolol/metabolism , Pyridinium Compounds/analysis , Spectrometry, Mass, Electrospray Ionization/methods , Alkylation , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme System/metabolism , Electrochemical Techniques , Hydroxylation , Oxidation-Reduction , Pyridines/chemistry , Pyridinium Compounds/isolation & purification , Signal TransductionABSTRACT
BACKGROUND: Calycosin (CAL), a type of O-methylated isoflavone extracted from the herb Astralagusmembranaceus (AM), is a bioactive chemical with antioxidative, antiphlogistic and antineoplastic activities commonly used in traditional alternative Chinese medicine. AM has been shown to confer health benefits as an adjuvant in the treatment of a variety of diseases. AIM: The main objective of this study was to determine whether CAL influences the cytochrome P450 (CYP450) system involved in drug metabolism. METHODS: Midazolam, tolbutamide, omeprazole, metoprolol and phenacetin were selected as probe drugs. Rats were randomly divided into three groups, specifically, 5% Carboxymethyl cellulose (CMC) for 8 days (Control), 5% CMC for 7 days + CAL for 1 day (single CAL) and CAL for 8 days (conc CAL), and metabolism of the five probe drugs evaluated using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). RESULTS: No significant differences were observed for omeprazole and midazolam, compared to the control group. T max and t1/2 values of only one probe drug, phenacetin, in the conc CAL group were significantly different from those of the control group (T max h: 0.50±0.00 vs 0.23±0.15; control vs conc CAL). C max of tolbutamide was decreased about two-fold in the conc CAL treatment group (conc vs control: 219.48 vs 429.56, P<0.001). CONCLUSION: Calycosin inhibits the catalytic activities of CYP1A2, CYP2D6 and CYP2C9. Accordingly, we recommend caution, particularly when combining CAL as a modality therapy with drugs metabolized by CYP1A2, CYP2D6 and CYP2C9, to reduce the potential risks of drug accumulation or ineffective treatment.
Subject(s)
Cytochrome P-450 Enzyme Inhibitors/metabolism , Drugs, Chinese Herbal/metabolism , Isoflavones/metabolism , Animals , Cytochrome P-450 Enzyme Inhibitors/chemistry , Cytochrome P-450 Enzyme Inhibitors/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/pharmacology , Isoflavones/chemistry , Isoflavones/pharmacology , Medicine, Chinese Traditional , Metoprolol/chemistry , Metoprolol/metabolism , Midazolam/chemistry , Midazolam/metabolism , Omeprazole/chemistry , Omeprazole/metabolism , Phenacetin/chemistry , Phenacetin/metabolism , Rats , Tolbutamide/chemistry , Tolbutamide/metabolismABSTRACT
There is a need to develop in vitro dissolution methods that discriminate for particle size of the manipulated abuse deterrent formulation (ADF) and that can be used for in vivo predictive models since dissolution methods developed for intact formulation might not be suitable for manipulated ones. A vertical diffusion cell (VDC) and United States Pharmacopeia (USP) Apparatus 1, 2, and 4 were evaluated for measuring the dissolution of intact and manipulated metoprolol succinate tablets with abuse deterrent-like properties. These tablets were physically manipulated to produce fine (106-500 µm) and coarse (500-1000 µm) powder samples. The VDC method was not able to discriminate the effect of particle size on drug release with varied stirring rate (200 to 800 rpm), molecular weight cut-off (MWCO, 3-5 kDa to 12-14 kDa) of the diffusion membrane, or composition and ionic strength (0.45% and 0.9%) of receiver medium. Standard and modified USP Apparatus 1 and 2 methods were assessed; however, large variations (RSD > 20%) were observed with USP Apparatus 1 for manipulated product dissolution and floating powder samples caused failure of auto-sampling when using standard USP Apparatus 2. For the USP Apparatus 4 dissolution method, packing configuration (1, 3, 8 layers and blend), ionic strength of dissolution medium (0.017, 0.077, and 0.154 M additional NaCl), and flow rate (4, 8, 16 mL/min) were studied to discriminate the effect of particle size on release. The USP Apparatus 4 dissolution method was optimized by using a packaging configuration of 8 layers with 8 mL/min flow rate which exhibited low variability and complete drug release and it could be used for in vivo predictive models. The dissolution method variables can be optimized for a specific product for desirable reproducibility and discriminatory power when using USP Apparatus 4.
Subject(s)
Abuse-Deterrent Formulations , Drug Compounding/methods , Drug Liberation , Prescription Drug Misuse/prevention & control , Diffusion , Metoprolol/administration & dosage , Metoprolol/chemistry , Models, Theoretical , Molecular Weight , Particle Size , Powders , Solubility , TabletsABSTRACT
The degradation of metoprolol (MTP), a ß-blocker commonly used for cardiovascular diseases, by UV/chlorine and UV/H2O2 processes was comparatively evaluated. MTP direct photolysis at 254â¯nm could be neglected, but remarkable MTP degradation was observed in both the UV/chlorine and UV/H2O2 systems. Compared with UV/H2O2, UV/chlorine has a more pronounced MTP degradation efficiency. In addition to primary radicals (OH and Cl), secondary radicals (ClO and Cl2-) played a pivotal role in degrading MTP by UV/chlorine process. The relative contributions of hydroxyl radicals (OH) and reactive chlorine species (RCS) in the UV/chlorine system varied at different solution pH values (i.e., the contribution of RCS increased from 57.7% to 75.1% as the pH increased from 6 to 8). The degradation rate rose as the oxidant dosage increased in the UV/chlorine and UV/H2O2 processes. The presence of Cl- slightly affected MTP degradation in both processes, while the existence of HCO3- and HA inhibited MTP degradation to different extents in both processes. In terms of the overall cost of electrical energy, UV/chlorine is more cost efficient than UV/H2O2. The degradation products during the two processes were identified and compared, and the degradation pathways were proposed accordingly. Compared with the direct chlorination of MTP, pre-oxidation with UV/chlorine and UV/H2O2 significantly enhanced the formation of commonly known DBPs. Therefore, when using UV/chlorine and UV/H2O2 in real waters to remove organic pollutants, the possible risk of enhanced DBP formation resulting from the degradation of certain pollutants during post-chlorination should be carefully considered.
Subject(s)
Adrenergic beta-1 Receptor Antagonists/chemistry , Chlorine/chemistry , Hydrogen Peroxide/chemistry , Metoprolol/chemistry , Ultraviolet Rays , Chlorides , Halogenation , Hydroxyl Radical , Models, Chemical , Oxidation-Reduction , Photolysis , Water Purification/methodsABSTRACT
The impact of electrolytes on the adsorption of emerging pollutants: pharmaceuticals onto layered materials: a raw clay mineral and its nonionic and cationic organoclay derivatives was studied. The selected pharmaceuticals: amoxicillin, norfloxacin, sulfamethoxazole, metoprolol, carbamazepine, and trimethoprim show different electric charges: zwitterionic, anionic, cationic and neutral and hydrophobic character (different LogP). Without any salts, the set of complementary data obtained by UV and infrared spectroscopies, X-ray diffraction points out the importance of the electric charge which represents a key parameter in both the spontaneity and feasibility of the adsorption. In contrast, the hydrophobicity of the analytes plays a minor role but determines the magnitude of the adsorbed amount of pharmaceuticals onto organoclays. With a dual hydrophilic and hydrophobic behavior, nonionic organoclay appears to be the most polyvalent material for the removal of the pharmaceuticals. In the presence of electrolytes (NaCl at a concentration of 1â¯×â¯10-2â¯molâ¯L-1), both nonionic and cationic organoclays show a decrease of their efficiencies, whereas the adsorption is particularly enhanced for Na-Mt except for the cationic species (trimethoprim and metoprolol). Thus, in realistic experimental conditions close to those of natural effluents, raw clay mineral appears as the most appropriate sorbent for the studied pharmaceuticals while it raises the question of the usefulness of organoclays in water remediation strategy.
Subject(s)
Electrolytes/chemistry , Environmental Restoration and Remediation/methods , Pharmaceutical Preparations/analysis , Soil Pollutants/analysis , Soil/chemistry , Water Pollutants, Chemical/analysis , Adsorption , Amoxicillin/analysis , Amoxicillin/chemistry , Carbamazepine/analysis , Carbamazepine/chemistry , Cations/analysis , Hydrophobic and Hydrophilic Interactions , Metoprolol/analysis , Metoprolol/chemistry , Norfloxacin/analysis , Norfloxacin/chemistry , Pharmaceutical Preparations/chemistry , Soil Pollutants/chemistry , Sulfamethoxazole/analysis , Sulfamethoxazole/chemistry , Trimethoprim/analysis , Trimethoprim/chemistry , Water/chemistry , Water Pollutants, Chemical/chemistry , X-Ray DiffractionABSTRACT
A wooden stick coated with a novel graphene-based nanocomposite (Graphene oxide/polyethylene glycol (GO/PEG)) is introduced and investigated for its efficacy in solid phase microextraction techniques. The GO/PEG-stick was prepared and subsequently applied for the extraction of ß-blockers, acebutolol, and metoprolol in human oral fluid samples, which were subsequently detected by liquid chromatography tandem mass spectrometry (LC-MS/MS). Experimental parameters affecting the extraction protocol including sample pH, extraction time, desorption time, appropriate desorption solvent, and salt addition were optimized. Method validation for the detection from oral fluid samples was performed following FDA (Food and Drug Administration) guidelines on bioanalytical method validation. Calibration curves ranging from 5.0 to 2000 nmol L-1 for acebutolol and 25.0 to 2000 nmol L-1 for metoprolol were used. The values for the coefficient of determination (R2) were found to be 0.998 and 0.996 (n = 3) for acebutolol and metoprolol, respectively. The recovery of analytes during extraction was 80.0% for acebutolol and 62.0% for metoprolol, respectively. The limit of detections (LODs) were 1.25, 8.00 nmol L-1 for acebutolol and metoprolol and the lower limit of quantifications (LLOQ) were 5.00 nmol L-1 for acebutolol and 25.0 nmol L-1 for metoprolol. Validation experiments conducted with quality control (QC) samples demonstrated method accuracy between 80.0% to 97.0% for acebutolol and from 95.0% to 109.0% for metoprolol. The inter-day precision for QC samples ranged from 3.6% to 12.9% for acebutolol and 9.5% to 11.3% for metoprolol. Additionally, the GO/PEG-stick was demonstrated to be reusable, with the same stick observed to be viable for more than 10 extractions from oral fluid samples.
Subject(s)
Acebutolol/isolation & purification , Adrenergic beta-Antagonists/isolation & purification , Metoprolol/isolation & purification , Solid Phase Microextraction/methods , Acebutolol/chemistry , Adrenergic beta-Antagonists/chemistry , Body Fluids/chemistry , Chromatography, Liquid , Graphite/chemistry , Humans , Limit of Detection , Metoprolol/chemistry , Mouth/chemistry , Nanocomposites/chemistry , Polyethylene Glycols/chemistry , Tandem Mass SpectrometryABSTRACT
Thanks to highly active antiretroviral treatments, HIV infection is now considered as a chronic condition. Consequently, people living with HIV (PLWH) live longer and encounter more age-related chronic co-morbidities, notably cardiovascular diseases, leading to polypharmacy. As the management of drug-drug interactions (DDIs) constitutes a key aspect of the care of PLWH, the magnitude of pharmacokinetic DDIs between cardiovascular and anti-HIV drugs needs to be more thoroughly characterized. To that endeavour, an UHPLC-MS/MS bioanalytical method has been developed for the simultaneous determination in human plasma of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin and its active metabolites. Plasma samples were subjected to protein precipitation with methanol, followed by evaporation at room temperature under nitrogen of the supernatant, allowing to attain measurable plasma concentrations down to sub-nanogram per milliliter levels. Stable isotope-labelled analytes were used as internal standards. The five drugs and two metabolites were analyzed using a 6-min liquid chromatographic run coupled to electrospray triple quadrupole mass spectrometry detection. The method was validated over the clinically relevant concentrations ranging from 0.3 to 480 ng/mL for amlodipine, atorvastatin and p-OH-atorvastatin, and 0.4 to 480 ng/mL for pravastatin, 0.5 to 480 ng/mL for rosuvastatin and o-OH-atorvastatin, and 3 to 4800 ng/mL for metoprolol. Validation performances such as trueness (95.4-110.8%), repeatability (1.5-13.4%) and intermediate precision (3.6-14.5%) were in agreement with current international recommendations. Accuracy profiles (total error approach) were lying within the limits of ±30% accepted in bioanalysis. This rapid and robust UHPLC-MS/MS assay allows the simultaneous quantification in plasma of the major currently used cardiovascular drugs and offers an efficient analytical tool for clinical pharmacokinetics as well as DDIs studies.
Subject(s)
Amlodipine/blood , Atorvastatin/blood , HIV Infections , Metoprolol/blood , Pravastatin/blood , Rosuvastatin Calcium/blood , Amlodipine/chemistry , Amlodipine/metabolism , Amlodipine/pharmacokinetics , Anti-HIV Agents/pharmacokinetics , Anti-HIV Agents/therapeutic use , Atorvastatin/chemistry , Atorvastatin/metabolism , Atorvastatin/pharmacokinetics , Chromatography, High Pressure Liquid/methods , Drug Interactions , HIV Infections/drug therapy , HIV Infections/metabolism , Humans , Linear Models , Metoprolol/chemistry , Metoprolol/metabolism , Metoprolol/pharmacokinetics , Pravastatin/chemistry , Pravastatin/metabolism , Pravastatin/pharmacokinetics , Reproducibility of Results , Rosuvastatin Calcium/chemistry , Rosuvastatin Calcium/metabolism , Rosuvastatin Calcium/pharmacokinetics , Sensitivity and Specificity , Tandem Mass Spectrometry/methodsABSTRACT
In this research, the volumetric scale-up law was assessed for its applicability to scale-up from a laboratory-scale extruder (11â¯mm diameter) to a pilot-scale extruder (16â¯mm diameter) with geometric similarity using low feed rates (0.1-0.26â¯kg/h at lab-scale). A sustained release formulation was extruded on both scales using scaled feed rates according to the volumetric scale-up law. The specific mechanical energies, drug solid-state, drug dissolution and the residence time distribution responses (i.e. axial mixing degree, mean residence time, width of distribution) were compared between both scales. The results showed that the difference in mean residence time between both scale extruders reduced with higher throughput and thus fill level. Overall, the specific mechanical energies (SME) were comparable between scales when using the volumetric scale-up law (i.e. applying scaling factor qâ¯=â¯3) and were exactly matching with a scaling factor of qâ¯=â¯2.6. Furthermore, plug flow conditions at lab-scale should be avoided before scaling up to obtain similar SMEs. The same degree of axial mixing (represented by the Peclet number) was demonstrated at a scaling factor of qâ¯=â¯2. If drug solid-state is a critical quality attribute (CQA), focus should be on the screw speed and cooling capacity of the larger scale extruder. The drug dissolution showed similarity between scales and was independent of drug solid-state for this formulation, indicating that successful scale-up was possible.
Subject(s)
Delayed-Action Preparations/chemistry , Technology, Pharmaceutical/methods , Drug Liberation , Metoprolol/chemistry , Polymethacrylic Acids/chemistryABSTRACT
Advancements on analytical strategies to determine the chemicals present in treated wastewater are necessary to clearly link their occurrence with the ecotoxicity of such effluents. This study describes the development of an integrated screening approach to determine the highest number of pharmaceutical transformation products (TPs) in a single run. The identification of TPs was based on the comparison of detected features with literature sources, compound prediction tools, in-house libraries and reference standards using high-resolution mass spectrometry (HRMS). This integrated approach allowed a better estimation (in silico) of the ecotoxicological contribution of the individual TPs identified. As a proof of concept, this methodology was applied for identification of the TPs generated from metoprolol and its main human metabolite (metoprolol acid) in pure water, hospital wastewater and industrial wastewater treated by UV/H2O2. Twenty-four TPs with potential ecotoxicological implications were identified and their presence was pinpointed as a function of the treated wastewater. An integrated screening approach has been developed using four different screening methodologies in the same run. Additionally, the metabolite MTPA has been considered as a target pollutant in UV/H2O2 experiments.
Subject(s)
Hazardous Substances/chemistry , Hydrogen Peroxide/chemistry , Metoprolol/chemistry , Pharmaceutical Preparations/chemistry , Ultraviolet Rays , Wastewater/chemistry , Water Pollutants, Chemical/chemistryABSTRACT
Implants offer the opportunity to improve patient adherence and real-world outcomes. However, most polymers used today are hydrophobic and limit drug properties suitable for development. Thermoplastic poly(urethanes) (TPUs) form pores upon hydration and may facilitate the development of implants containing drugs exhibiting broadly different properties. We sought to investigate the effect of drug physicochemical properties on permeability through membranes of varying TPU mixture composition; leverage imaging to visualize microstructural changes to the membrane across the TPU mixture composition range; and quantitatively characterize the membrane microstructure using equivalent pore analysis. We observed a correlation between drug hydrophobicity and its permeability through hydrophobic-rich TPU membranes. Conversely, all compounds diffused through hydrophilic-rich TPU membranes at similar rates, regardless of drug properties. Imaging revealed significant microstructure differences between hydrophobic-rich and hydrophilic-rich TPU membranes, supporting hypotheses proposed in our previous study. The hydrated hydrophilic TPU membrane pore area was determined to be 0.583% and its equivalent pore radius was found to be 128â¯nm, suggesting that hydrophilic TPU membranes may be used to modify the release of small molecular weight drugs and macromolecules. These findings highlight the benefits of hydrophilic TPUs as rate-controlling membranes to modulate the release rate of drugs with varying physicochemical properties.
Subject(s)
Membranes, Artificial , Polyurethanes/chemistry , Dextrans/chemistry , Diffusion , Drug Implants , Emtricitabine/chemistry , Fluorescein-5-isothiocyanate/analogs & derivatives , Fluorescein-5-isothiocyanate/chemistry , Hydrophobic and Hydrophilic Interactions , Ibuprofen/chemistry , Metoprolol/chemistry , Molecular Weight , Permeability , PorosityABSTRACT
This work shows that the metal organic framework (MOF) HKUST-1 of type Cu3(BTC)2 (also referred to as MOF-199; a face-centered-cubic MOF containing nanochannels) is a most viable coating for use in enantioseparation in capillary electrochromatography (CEC). A HKUST-1 modified capillary was prepared and characterized by scanning electron microscopy, transmission electron microscopy, Fourier transform infrared spectra, elemental analysis and thermogravimetric analysis. CEC-based enantioseparation of the basic drugs propranolol (PRO), esmolol (ESM), metoprolol (MET), amlodipine (AML) and sotalol (SOT) was performed by using carboxymethyl-ß-cyclodextrin as the chiral selector. Compared with a fused-silica capillary, the resolutions are improved (ESM: 1.79; MET: 1.80; PRO: 4.35; SOT: 1.91; AML: 2.65). The concentration of chiral selector, buffer pH value, applied voltage and buffer concentration were optimized, and the reproducibilities of the migration times and Rs values were evaluated. Graphical abstract Schematic presentation of the preparation of a HKUST-1@capillary for enantioseparation of racemic drugs. Cu(NO3)2 and 1,3,5-benzenetricarboxylic acid (BTC) were utilized to prepare the HKUST-1@capillary. Then the capillary was applied to construct capillary electrochromatography system with carboxymethyl-ß-cyclodextrin (CM-ß-CD) for separation of basic racemic drugs.
Subject(s)
Amlodipine/isolation & purification , Metal-Organic Frameworks/chemistry , Metoprolol/isolation & purification , Propanolamines/isolation & purification , Propranolol/isolation & purification , Sotalol/isolation & purification , Amlodipine/chemistry , Capillary Electrochromatography/instrumentation , Capillary Electrochromatography/methods , Metoprolol/chemistry , Propanolamines/chemistry , Propranolol/chemistry , Sotalol/chemistry , Stereoisomerism , beta-Cyclodextrins/chemistryABSTRACT
The objective of this research was to evaluate the impact of changes in the formulation of metoprolol extended-release (ER) tablets on dissolution, pharmacokinetic, and exercise-induced heart rate (EIHR) using a combined physiologically based absorption pharmacokinetic, and population pharmacokinetic/pharmacodynamic modeling and simulation approach. Using a previously developed physiologically based absorption pharmacokinetic model in DDDPlus and GastroPlus, we simulated the changes in drug release and exposure as the result of quantitative changes in the release-controlling excipient, hydroxylpropylmethylcellulose, for 50 and 200 mg. The similarity of dissolution profiles was assessed using the f2 test, and bioequivalence was tested on the simulated pharmacokinetic profiles. We used the simulated concentration-time profiles following formulation changes as pharmacokinetic input into a population pharmacokinetic/pharmacodynamic model newly developed in NONMEM to determine if changes in pharmacokinetics lead to clinically significant changes in pharmacodynamics. Pharmacodynamic assessment was based on the percentage reduction in the EIHR from baseline. Therapeutic effect was considered similar when the model-predicted EIHR was within 50% to 85% of the average maximum EIHR of healthy 30-year-old subjects. A 40% or more increase in the release rate constant resulted in dissimilarity in dissolution profiles and bioINequivalence in pharmacokinetics for both 50 and 200 mg. Formulation-related differences in drug release of metoprolol ER tablets can lead to differences in pharmacokinetics. However, the evaluated pharmacokinetic differences do not lead to clinically meaningful differences in EIHR, suggesting that EIHR may not be sensitive enough to detect changes in pharmacokinetics of metoprolol ER products.
Subject(s)
Delayed-Action Preparations/chemistry , Metoprolol/chemistry , Area Under Curve , Chemistry, Pharmaceutical/methods , Delayed-Action Preparations/pharmacokinetics , Drug Liberation/physiology , Excipients/chemistry , Heart Rate/drug effects , Humans , Metoprolol/pharmacokinetics , Tablets/chemistry , Tablets/pharmacokinetics , Therapeutic EquivalencyABSTRACT
Mesoporous silica nanoparticles (MSNs) have been widely studied as drug carriers to get sustained release behaviors, however, their application in sustained release of metoprolol tartrate (MPT) is limited. The possible reason is due to MPT molecule being bulky, while normal type MSNs like MCM-41 and SBA-15 have pore sizes of only 3-6â¯nm. In this study, two MCF-26 type MSNs were prepared with pore size of 11 or 15â¯nm, and used to conduct MPT release in comparison with MCM-41 and SBA-15. Both molecular simulation and MPT release experiments were performed to identify the pore size effect on adsorption and diffusion (release) of MPT in these MSNs. Finally, a kind of pH-sensitive MPT drug delivery system was obtained by coating the chosen MCF-26@MPT with an enteric polymer, which might find promising application in treating morning hypertension attack by orally administrating the drug delivery system before bedtime.
Subject(s)
Drug Liberation , Metoprolol/pharmacology , Molecular Dynamics Simulation , Silicon Dioxide/chemistry , Acrylic Resins/chemistry , Adsorption , Dynamic Light Scattering , Hydrogen-Ion Concentration , Metoprolol/chemistry , Molecular Conformation , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Nitrogen/chemistry , Particle Size , PorosityABSTRACT
Metoprolol {systematic name: (RS)-1-isopropylamino-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol}, C15H25NO3, is a cardioselective ß1-adrenergic blocking agent that shares part of its molecular skeleton with a large number of other ß-blockers. Results from its solid-state characterization by single-crystal and variable-temperature powder X-ray diffraction and differential scanning calorimetry are presented. Its molecular and crystal arrangements have been further investigated by molecular modelling, by a Cambridge Structural Database (CSD) survey and by Hirshfeld surface analysis. In the crystal, the side arm bearing the isopropyl group, which is common to other ß-blockers, adopts an all-trans conformation, which is the most stable arrangement from modelling data. The crystal packing of metoprolol is dominated by an O-H...N/N...H-O pair of hydrogen bonds (as also confirmed by a Hirshfeld surface analysis), which gives rise to chains containing alternating R and S metoprolol molecules extending along the b axis, supplemented by a weaker O...H-N/N-H...O pair of interactions. In addition, within the same stack of molecules, a C-H...O contact, partially oriented along the b and c axes, links homochiral molecules. Amongst the solid-state structures of molecules structurally related to metoprolol deposited in the CSD, the ß-blocker drug betaxolol shows the closest analogy in terms of three-dimensional arrangement and interactions. Notwithstanding their close similarity, the crystal lattices of the two drugs respond differently on increasing temperature: metoprolol expands anisotropically, while for betaxolol, an isotropic thermal expansion is observed.
Subject(s)
Adrenergic beta-1 Receptor Antagonists/chemistry , Metoprolol/chemistry , Betaxolol/chemistry , Calorimetry, Differential Scanning , Computer Simulation , Crystallography, X-Ray , Databases, Chemical , Hydrogen Bonding , Molecular Dynamics Simulation , Molecular Structure , Powder DiffractionABSTRACT
Porphyrins are known as effective photosensitizers and can be an interesting key in phototreatment of water contaminated with micropollutants such as pharmaceuticals. They already showed to be efficient photocatalysts for the degradation of dyes, chlorophenols and other pollutants. This work demonstrates the applicability of 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin (H2TF5PP) as photosensitizer for treatment of water contaminated with metoprolol, a highly prescribed ß-blocker, which is not completely removed in sewage treatment plants. Studies were firstly developed under homogeneous conditions with simulated solar radiation and porphyrin was found to be efficient in the photodegradation of metoprolol, following a pseudo-first order kinetics with ca. 90% metoprolol degradation after 12 h. Experiments in presence of scavengers confirmed the mechanism of degradation via singlet oxygen. Appearance of several new peaks in HPLC chromatograms indicates the formation of products, identified by HPLC-MSn. Furthermore, the porphyrin was immobilized on a silica support and used as heterogeneous photocatalyst in degradation of metoprolol. Experiments using this heterogeneous photocatalyst under real solar irradiation were also performed, and similar results were obtained. Kinetic comparison of metoprolol photodegradation in buffer solution and in real wastewater treatment plant effluent showed that the efficiency of the immobilized porphyrin was not decreased by the complex matrix of the effluent.
Subject(s)
Adrenergic beta-1 Receptor Antagonists/chemistry , Metoprolol/chemistry , Photosensitizing Agents/radiation effects , Porphyrins/radiation effects , Sunlight , Water Pollutants, Chemical/chemistry , Photolysis , Photosensitizing Agents/chemistry , Porphyrins/chemistry , Singlet Oxygen/chemistry , Water Purification/methodsABSTRACT
The solubilities of metoprolol succinate (a cardioselective ß1 adrenergic receptor) in methanol, ethanol, n-propanol, isopropanol, n-butanol, ethyl acetate, and acetone were measured at temperatures ranging from (278.2 to 318.2) K using a solidâ»liquid equilibrium method. The solubility of metoprolol succinate increases with increasing temperature. At a fixed temperature, the solubility decreases in the order methanol > ethanol > n-butanol > n-propanol > isopropanol > acetone > ethyl acetate. The enthalpy of fusion and the melting point of metoprolol succinate were determined by differential scanning calorimetry. The thermodynamic properties of the dissolution process, determined by a van't Hoff analysis, have been obtained and are discussed. The modified Apelblat equation, Wilson model, and non-random two-liquid (NRTL) model were employed to correlate the solubilities of metoprolol succinate in different solvents. Finally, a quantitative structureâ»property relationship (QSPR) study of physical properties of solvents and density functional theory simulations of hydrogen-bonding structure were carried out to give the explanation for the sequence of solubility in alcohols. The density functional theory (DFT) calculations well illustrated that the solubility of metoprolol succinate in various alcohols can be mainly attributed to the intra- and intermolecular hydrogen bonds in metoprolol succinate-solvent complexes.